Clinical Trials
6 trialsNCT01685814 2023-04-27
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Wuerzburg University Hospital
Phase 3 Unknown
NCT01554852 2018-06-11
Myeloma XI
University of Leeds
Phase 3 Unknown
NCT03345303 2017-11-17
Bortezomib in Intrahepatic Cholangiocellular Carcinoma
Eastern Hepatobiliary Surgery Hospital
Phase 3 Unknown
NCT01449344 2017-03-07
(R-HAD)
European Mantle Cell Lymphoma Network
Phase 3 Unknown
NCT02362165 2016-04-20
CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma
Sun Yat-sen University
Phase 3 Unknown
NCT01134484 2012-07-20
VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Phase 3 Unknown